CEP 2563
a lysinyl-beta-alanyl ester of CEP-751; structure in first source
Also Known As:
CEP-2563; CEP2563
Networked: 3
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Janisch, Linda:
1 article
(11/2004)
|
| 2. | Mani, Sridhar:
1 article
(11/2004)
|
| 3. | Mauer, Ann M:
1 article
(11/2004)
|
| 4. | Ratain, Mark J:
1 article
(11/2004)
|
| 5. | Undevia, Samir D:
1 article
(11/2004)
|
| 6. | Vogelzang, Nicholas J:
1 article
(11/2004)
|
| 7. | Ball, Douglas W:
1 article
(09/2003)
|
| 8. | Denmeade, Samuel R:
1 article
(09/2003)
|
| 9. | Dionne, Craig:
1 article
(09/2003)
|
| 10. | Jones-Bolin, Susan:
1 article
(09/2003)
|
Related Diseases
| 1. | Neoplasms (Cancer)
11/01/2004
- " A Phase I clinical trial involving 18 patients was conducted to determine the toxicity profile, maximum tolerated dose (MTD), toxicity profile, and pharmacokinetics of CEP-2563 in patients with advanced solid tumors refractory to standard therapy. " 11/01/2004
- " Preclinical models have demonstrated that both CEP-751 and CEP-2563 have antitumor activity in a variety of tumors. " 11/01/2004
- " Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors." 09/01/2003
- " CEP-751 and its prodrug, CEP-2563, also inhibited tumor growth in MTC cell xenografts. " 09/01/1999
- " This review presents the hypothesis of the neurotrophin-trk receptors as a viable molecular target for medicinal chemical intervention in tumor biology, followed by an overview of the pre-clinical studies which culminated in the advancement of the first potent trk tyrosine kinase inhibitor CEP-2563 (KT-8391), and the orally active K-252a analog, CEP-701 (KT-5555) into clinical evaluation."
|
|
Related Drugs and Biologics
Related Therapies and Procedures